Publication:
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Simple item page
dc.contributor.authorStahl, Maximilian
dc.contributor.authorDeVeaux, Michelle
dc.contributor.authorMontesinos, Pau
dc.contributor.authorItzykson, Raphaël
dc.contributor.authorRitchie, Ellen K
dc.contributor.authorSekeres, Mikkael A
dc.contributor.authorBarnard, John
dc.contributor.authorPodoltsev, Nikolai A
dc.contributor.authorBrunner, Andrew
dc.contributor.authorKomrokji, Rami S
dc.contributor.authorBhatt, Vijaya R
dc.contributor.authorAl-Kali, Aref
dc.contributor.authorCluzeau, Thomas
dc.contributor.authorSantini, Valeria
dc.contributor.authorRoboz, Gail J
dc.contributor.authorFenaux, Pierre
dc.contributor.authorLitzow, Mark
dc.contributor.authorFathi, Amir T
dc.contributor.authorPerreault, Sarah
dc.contributor.authorKim, Tae Kon
dc.contributor.authorPrebet, Thomas
dc.contributor.authorVey, Norbert
dc.contributor.authorVerma, Vivek
dc.contributor.authorGerming, Ulrich
dc.contributor.authorBergua, Juan
dc.contributor.authorSerrano, Josefina
dc.contributor.authorGore, Steven D
dc.contributor.authorZeidan, Amer M
dc.date.accessioned2023-01-25T10:20:42Z
dc.date.available2023-01-25T10:20:42Z
dc.date.issued2018-07-02
dc.identifier.doi10.1080/10428194.2018.1468893
dc.identifier.essn1029-2403
dc.identifier.pmid29963936
dc.identifier.unpaywallURLhttps://flore.unifi.it/bitstream/2158/1173639/2/stahl2018_MRC%20e%20LRF.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12666
dc.issue.number1
dc.journal.titleLeukemia & lymphoma
dc.journal.titleabbreviationLeuk Lymphoma
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.page.number246-249
dc.pubmedtypeLetter
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshFemale
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Assessment
dc.subject.meshRisk Factors
dc.subject.meshSurvival Analysis
dc.subject.meshTransplantation, Homologous
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titlePerformance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
dc.typeresearch article
dc.type.hasVersionSMUR
dc.volume.number60
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía